Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Tissue Regenix Group (TRX)

Price 59.00p on 31-01-2025 at 17:30:01
Change 1.00p 1.72%
Buy 60.00p
Sell 58.00p
Buy / Sell TRX Shares
Last Trade: Unknown 200,000.00 at 58.23p
Day's Volume: 62,370
Last Close: 59.00p
Open: 59.00p
ISIN: GB00BNTXR104
Day's Range 59.00p - 59.00p
52wk Range: 52.00p - 74.00p
Market Capitalisation: £42m
VWAP: 58.00112p
Shares in Issue: 71m

Recent Trades History Tissue Regenix Group (TRX)

Buy/Sell Volume Trade Prc Trade Type Trade Time
Unknown* 200,000 58.23p Negotiated Trade
14:53:31 - 30-Jan-25
Sell* 200 58.16p Ordinary
15:03:04 - 31-Jan-25
Sell* 26 58.16p Ordinary
15:00:35 - 31-Jan-25
Sell* 704 58.00p Ordinary
13:35:09 - 31-Jan-25
Sell* 1,718 58.00p Ordinary
12:38:43 - 31-Jan-25
Sell* 23 58.80p Ordinary
12:06:43 - 31-Jan-25
Sell* 1 58.16p Ordinary
11:00:39 - 31-Jan-25
Sell* 803 58.00p Ordinary
10:57:01 - 31-Jan-25
Sell* 43 58.16p Ordinary
10:56:10 - 31-Jan-25
Sell* 10,000 58.00p Ordinary
10:27:36 - 31-Jan-25

Share Price History for Tissue Regenix Group

Time period:
to
Date Open High Low Close Volume

Share News for Tissue Regenix Group

IN BRIEF: Tissue Regenix eyes profit beat; plots German jv disposal

31st Jan 2025 21:30

Tissue Regenix Group PLC - Leeds, England-based regenerative medical devices company - Revenue increases 8% to USD28.4 million in the year ending December 31 from USD26.3 million a year prior. In addition, expects to report an adjusted earnings before interest, tax, depreciation and amortisation above expectations. Notes this will mark the second full year of profitability for Tissue Regenix and the fourth year of above-market growth. Read More

IN BRIEF: Tissue Regenix contacts firms as it considers possible sale

4th Nov 2024 18:21

Tissue Regenix Group PLC - Leeds, England-based regenerative medical devices company - In response to press reports, say that it is conducting a review of strategic options, which may include soliciting offers for Tissue Regenix. Accordingly, the firm has contacted a limited number of potential counterparties to assess whether they could put forward a proposal "that would deliver greater value to Tissue Regenix's shareholders than pursuing a standalone independent strategy". Says it has not received any indicative non-binding proposals to date, and says there can be no certainty any offer will be made. Read More

EARNINGS AND TRADING: Blackbird loss narrows; Futura Medical in profit

10th Sep 2024 21:21

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News: Read More

UK earnings, trading statements calendar - next 7 days

3rd Sep 2024 11:31

Read More

IN BRIEF: Tissue Regenix eyes revenue and adjusted profit growth

16th Jul 2024 11:30

Tissue Regenix Group PLC - Leeds, England-based regenerative medical devices company - Says trading in the first half of 2024 was strong, as it expects revenue to have climbed 16% to USD16.4 million from USD14.1 million a year prior. "The BioRinse segment continued to deliver solid growth driven by increased efficiencies, while the commercial reorganisation of the dCELL segment continued to show benefits, demonstrating robust growth within the period," Tissue Regenix says. It will report its full half-year results on September 10. Read More

FTSE 100 Latest
Value8,673.96
Change27.08

Login to your account

Forgot Password?

Not Registered